Sterling Pharma Acquires NewChem Technologies

Sterling Pharma Solutions acquired UK-based NewChem Technologies, a contract services provider focused on organic chemistry and supplying customers across a range of industries such as pharmaceuticals, diagnostics, and biotechnology, according to the press release.

Sterling is known as a global contract development and manufacturing organization, and their network spreads to a manufacturing site in Cramlington, United Kingdom, a recently GMP-licensed dedicated bioconjugation facility in Deeside, and a 111-acre site in Ringaskiddy, Ireland.

The acquisition of NewChem adds further scientific resource and expertise to Sterling’s chemistry services while finding ways to synthesize customers’ molecules and establish a place in development and scale up. The financial details were not disclosed, but the deal includes all of NewChem’s assets and employees. Additionally, the founders of NewChem, Bob Tyson and Bernard Golding, will continue in their roles as site head and science director.

The site, located within Newcastle, will work hand-in-hand with the Sterling facility in Cary, NC, which operates as an early-phase development center, according to the press release.

“Over the last three years, Sterling has grown significantly, both organically and through a global strategy of acquisitions, and this latest deal marks the next step that will help us achieve our aim of becoming the preferred partner and provider of small molecule services to the pharmaceutical industry,” said Kevin Cook, CEO at Sterling, in a press release. “The expertise and experience within the well-respected and talented NewChem team will provide the business with additional capacity to solve complex chemistry challenges. NewChem’s connections with academia is closely aligned with Sterling’s Technology and Innovation Program, which sees us work with a number of leading global academic institutions to bring the latest technologies and innovations to our customers.”

Source: Sterling